BCDA BioCardia

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to . Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: .

A webcast replay of the call will be available approximately one hour after the end of the call through June 26, 2024 at the above links. A telephonic replay of the call will be available through April 10, 2024 and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 3499879.

About BioCardia®

, headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. BioCardia also works with partners to provide its proprietary Helix transendocardial biotherapeutic delivery system, as well as technology and services for the development and commercialization of partners’ therapeutic agents. For more information visit .

MEDIA CONTACT:

Miranda Peto, Marketing / Investor Relations



(650) 226-0120

INVESTOR CONTACT:

David McClung, Chief Financial Officer



(650) 226-0120



EN
20/03/2024

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Re...

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. Study clinical cardiology leadership and members of the Executive Steering Committee, Dr. Carl Pepine, Professor of Medicine a...

May 1, 2024 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatm...

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy i...

April 25, 2024 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlight...

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below. “Heart failure of redu...

March 27, 2024 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Host 2023 Financial Results and Corporate Update Conferen...

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conferen...

March 20, 2024 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia’s biotherapeutic delivery system with established safety profile enables minimally invasive transplantation of StemCardia’s off-the-shelf cardiac muscle cells SUNNYVALE, Calif., March 13, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, and , a biotechnology company focused on cell and gene therapy ...

March 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch